Helus Pharma Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)0.70 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $11.91Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $870.1M Shares Outstanding 73.1M diluted Next Earnings Date20 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Helus Pharma Inc. (formerly Cybin Inc.) is a clinical-stage biopharmaceutical company at a major development inflection point as it transitions toward a commercial-ready organization. The company's primary value driver is HLP003, a proprietary deuterated psilocin analog holding FDA Breakthrough Therapy Designation for the adjunctive treatment of major depressive disorder (MDD). With the Phase 3 APPROACH trial fully enrolled ahead of schedule and topline data expected in November 2026, Helus is positioned for asymmetric upside. While Phase 2 data for its GAD candidate (HLP004) raised dosing questions, the company's robust balance sheet—bolstered by a $50 million capital raise in June 2026—provides operational runway into 2027, mitigating near-term financing risks. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$7.99 Mean target$37.58 High · most bullish analyst$69.88 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $7.9920% The Phase 3 APPROACH trial fails to show a statistically significant benefit over placebo, or reveals unexpected safety concerns. Additionally, regulatory hurdles or clinical delays emerge for HLP004 due to the ambiguous dose-response profile seen in Phase 2, forcing a costly redesign of the program and depleting cash reserves faster than expected. Base CaseCentral scenario $37.5850% Matches the consensus meanHLP003 APPROACH trial meets its primary endpoint of statistically significant MADRS reduction at 6 weeks with a clean safety profile, confirming its therapeutic potential. The company successfully aligns with the FDA on the HLP004 GAD clinical path by late 2026 and appoints a permanent CEO with strong commercialization credentials. The stock trades closer to consensus analyst targets. Bull CaseUpside scenario $69.8830% The Phase 3 APPROACH trial of HLP003 delivers outstanding topline efficacy and safety data in November 2026, matching or exceeding the 100% response and 71% remission rates seen in Phase 2. This de-risks the second Phase 3 trial (EMBRACE) and accelerates FDA NDA submission toward 2028. Strong data triggers partnership interest from Big Pharma, driving significant upward repricing. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |